ABSTRACT
OBJECTIVES: Genetic determinants conferring resistance to macrolide, lincosamide, and streptogramin B (MLSB) via ribosomal modification such as, erm, msrA/B and ereA/B genes are distributed in bacteria. The main goals of this work were to evaluate the dissemination of MLSB resistance phenotypes and genotypes in methicillin-resistant Staphylococcus aureus (MRSA) isolates collected from clinical samples. METHODS: A total of 106 MRSA isolates were studied. Isolates were recovered from 3 hospitals in Tehran between May 2016 to July 2017. The prevalence of MLSB-resistant strains were determined by D-test, and then M-PCR was performed to identify genes encoding resistance to macrolides, lincosamides, and streptogramins in the tested isolates. RESULTS: The frequency of constitutive resistance MLSB, inducible resistance MLSB and MSB resistance were 56.2%, 22.9%, and 16.6%, respectively. Of 11 isolates with the inducible resistance MLSB phenotype, ermC, ermB, ermA and ereA were positive in 81.8%, 63.6%, 54.5% and 18.2% of these isolates, respectively. In isolates with the constitutive resistance MLSB phenotype, the prevalence of ermA, ermB, ermC, msrA, msrB, ereA and ereB were 25.9%, 18.5%, 44.4%, 0.0%, 0.0%, 11.1% and 0.0%, respectively. CONCLUSION: Clindamycin is commonly administered in severe MRSA infections depending upon the antimicrobial susceptibility findings. This study showed that the D-test should be used as an obligatory method in routine disk diffusion assay to detect inducible clindamycin resistance in MRSA so that effective antibiotic treatment can be provided.
Subject(s)
Bacteria , Clindamycin , Diffusion , Drug Resistance , Genotype , Lincosamides , Macrolides , Methicillin-Resistant Staphylococcus aureus , Methods , Phenotype , Prevalence , Staphylococcus aureus , Staphylococcus , Streptogramin B , StreptograminsSubject(s)
Humans , Chickenpox/complications , Lincosamides/pharmacology , Macrolides/pharmacology , Staphylococcal Infections/complications , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Streptococcal Infections/complications , Streptococcal Infections/drug therapy , Streptococcus pyogenes/drug effects , Streptogramins/pharmacology , Drug Resistance, Microbial , Microbial Sensitivity TestsABSTRACT
Se realizó una revisión de artículos publicados sobre las estreptograminas, una familia de antimicrobianos para el tratamiento de sepsis por gérmenes grampositivos. Se exponen las principales características y utilidades de quinupristina y dalfopristina, principios activos que componen Synercid®. Este medicamento constituye una alternativa para el tratamiento de cepas grampositivas resistentes a los glucopéptidos